The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Open accessPublished version of a preprint
Abstract
BACKGROUND: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. METHODS: We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19. We used a standard enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)-heparin antibodies and a modified (PF4-enhanced) platelet-activation test to detect platelet-activating antibodies under various reaction conditions. Included in this testing were samples from patients who had blood samples referred for investigation of vaccine-associated thrombotic events, with 28 testing positive on a screening PF4-heparin immunoassay. RESULTS: Of the 11 original patients, 9 were women, with a median age of 36 years (range, 22 to 49). Beginning 5 to 16 days after vaccination, the patients presented with one or more thrombotic events, with the exception of 1 patient, who presented with fatal intracranial hemorrhage. Of the patients with one or more thrombotic events, 9 had cerebral venous thrombosis, 3 had splanchnic-vein thrombosis, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died. Five patients had disseminated intravascular coagulation. None of the patients had received heparin before symptom onset. All 28 patients who tested positive for antibodies against PF4-heparin tested positive on the platelet-activation assay in the presence of PF4 independent of heparin. Platelet activation was inhibited by high levels of heparin, Fc receptor-blocking monoclonal antibody, and immune globulin (10 mg per milliliter). Additional studies with PF4 or PF4-heparin affinity purified antibodies in 2 patients confirmed PF4-dependent platelet activation. CONCLUSIONS: Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. (Funded by the German Research Foundation.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thrombocytopenia and immune thrombocytopenia (ITP) were also included due to their association with TTS and reports of ITP as an independent safety signal [7,19,20].”
From COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-1932 and Ad26.COV2.S (Johnson & Johnson–Janssen) Covid-19 vaccines,33 both of which are adenoviral vector vaccines.”
From Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuker, A. C., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 755
Self-citationCLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
Greinacher, A. (2015) · PubMed · doi:10.1056/nejmcp1411910 · Cited by 612
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis
Warkentin, T. E., & Kelton, J. G. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-7-200110020-00009 · Cited by 463
Self-citationAutoimmune heparin‐induced thrombocytopenia
Greinacher, A., Selleng, K., & Warkentin, T. E. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13813 · Cited by 414
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia
Rice, L., Attisha, W. K., Drexler, A. J., & Francis, J. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00009 · Cited by 268
Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S., & Lillicrap, D. (2006) · Blood · doi:10.1182/blood-2006-06-032524 · Cited by 220
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
Warkentin, T. E., Pai, M., & Linkins, L. (2017) · Blood · doi:10.1182/blood-2017-04-778993 · Cited by 210
Self-citationWarkentin, T. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1636645 · Cited by 180
Self-citationA Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
Warkentin, T. E., Makris, M., Jay, R. M., & Kelton, J. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.012 · Cited by 170
Self-citationJuhl, D., Eichler, P., Lübenow, N., Strobel, U., Wessel, A., & Greinacher, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00621.x · Cited by 170
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,001
Sessa, F., Salerno, M., Esposito, M., Nunno, N. R. D., Zamboni, P., & Pomara, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245876 · Cited by 60
Hertel, M., Heiland, M., Nahles, S., von Laffert, M., Mura, C., Bourne, P. E., Preißner, R., & Preißner, S. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18184 · Cited by 64
Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody
Wang, J. J., Armour, B., Chataway, T., Troelnikov, A., Colella, A. D., Yacoub, O., Hockley, S., Tan, C. W., & Gordon, T. P. (2022) · Blood · doi:10.1182/blood.2022016474 · Cited by 60
COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis
Pomara, C., Sessa, F., Ciaccio, M., Dieli, F., Esposito, M., Giammanco, A., Garozzo, S. F., Giarratano, A., Prati, D., Rappa, F., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11060955 · Cited by 59
Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story
Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100101 · Cited by 60
Benning, L., Töllner, M., Hidmark, A. S., Schaier, M., Nußhag, C., Kälble, F., Reichel, P., Buylaert, M., Grenz, J., Ponath, G. D., et al. (2021) · Vaccines · doi:10.3390/vaccines9080857 · Cited by 58
The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic
Tran, A., & Witek, T. J. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00397-6 · Cited by 59
Greinacher, A., Länger, F. P., Schönborn, L., Thiele, T., Haddad, M., Renné, T., Rollin, J., Gruel, Y., & Warkentin, T. E. (2021) · Haematologica · doi:10.3324/haematol.2021.280366 · Cited by 59
Self-citationBuske, C., Dreyling, M. H., Álvarez‐Larrán, A., Apperley, J. F., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Porta, M. G. D., Dimopoulos, M. A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100403 · Cited by 61
Bosaeed, M., Balkhy, H. H., Almaziad, S., Aljami, H. A., Alhatmi, H., Alanazi, H., Alahmadi, M., Jawhary, A., Alenazi, M. W., Almasoud, A., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00193-2 · Cited by 59
Lu, R. X. Z., Lai, B. F. L., Rafatian, N., Gustafson, D., Campbell, S. B., Banerjee, A., Kozak, R., Mossman, K., Mubareka, S., Howe, K. L., et al. (2022) · Lab on a Chip · doi:10.1039/d1lc00817j · Cited by 58
First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination
de Bruijn, S., Maes, M., Waele, L. D., Vanhoorelbeke, K., & Gadisseur, A. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15418 · Cited by 58
Al-Maqbali, J. S., Rasbi, S. A., Kashoub, M. S., Hinaai, A. M. A., Farhan, H., Rawahi, B. A., & Alawi, A. M. A. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.932946 · Cited by 58
Kerr, S., Joy, M., Torabi, F., Bedston, S., Akbari, A., Agrawal, U., Beggs, J., Bradley, D., Chuter, A., Docherty, A. B., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003927 · Cited by 59
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 56
Nachtigall, I., Bonsignore, M., Hohenstein, S., Bollmann, A., Günther, R., Kodde, C., Englisch, M., Ahmad‐Nejad, P., Schröder, A., Glenz, C., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07284-8 · Cited by 58
Douxfils, J., Favresse, J., Dogné, J., Lecompte, T., Susen, S., Cordonnier, C., Lebreton, A., Gosselin, R. C., Siè, P., Pernod, G., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.05.010 · Cited by 57
Shim, J., Ryu, K., Lee, S. H., Cho, E.-A., Lee, Y. J., & Ahn, J. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126549 · Cited by 56
Michele, M. D., Iacobucci, M., Chistolini, A., Nicolini, E., Pulcinelli, F. M., Cerbelli, B., Merenda, E., Schiavo, O. G., Sbardella, E., Berto, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25010-x · Cited by 66
Autoimmunity roots of the thrombotic events after COVID-19 vaccination
Elrashdy, F., Tambuwala, M. M., Hassan, S. S., Adadi, P., Seyran, M., El‐Aziz, T. M. A., Rezaei, N., Lal, A., Aljabali, A. A. A., Kandimalla, R. J. L., et al. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102941 · Cited by 57
Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination
Yocum, A. D., & Simon, E. L. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.05.001 · Cited by 56
Economic evaluation for mass vaccination against COVID-19
Wang, W., Fann, J. C., Chang, R., Jeng, Y., Hsu, C.-Y., Chen, H.-H., Liu, J., & Yen, A. M. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.05.020 · Cited by 56
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later
Angeli, F., Zappa, M., Reboldi, G., Trapasso, M., Cavallini, C., Spanevello, A., & Verdecchia, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.09.007 · Cited by 58
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19
Apostolidis, S. A., Sarkar, A., Giannini, H. M., Goel, R. R., Mathew, D., Suzuki, A., Baxter, A. E., Greenplate, A. R., Alanio, C., Abdel-Hakeem, M. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834988 · Cited by 59
Chui, C. S. L., Fan, M., Wan, E. Y. F., Leung, M. T. Y., Cheung, E. C. L., Yan, V. K. C., Gao, L., Ghebremichael‐Weldeselassie, Y., Man, K. K. C., Lau, K. K., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101504 · Cited by 56
Post-mortem findings in vaccine-induced thrombotic thombocytopenia
Pomara, C., Sessa, F., Ciaccio, M., Dieli, F., Esposito, M., Garozzo, S. F., Giarratano, A., Prati, D., Rappa, F., Salerno, M., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279075 · Cited by 55
A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
Heidari, S., Palmer-Ross, A., & Goodman, T. (2021) · Vaccines · doi:10.3390/vaccines9111322 · Cited by 54
Gando, S., & Wada, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649122 · Cited by 56
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination
Tang, L. V., & Hu, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01100-7 · Cited by 54
Goldman, M., & Hermans, C. R. J. R. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003648 · Cited by 54
Nasonov, E. L., Lila, A. M., Vi, M., Belov, B. S., Karateev, A. E., Дубинина, Т. В., Nikitinskaya, O. A., Baranov, A. A., Abdulganieva, D. I., Moiseev, S. V., et al. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-239-254 · Cited by 55
Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
McMillan, C. L. D., Choo, J. J. Y., Idris, A., Supramaniam, A., Modhiran, N., Amarilla, A. A., Isaacs, A., Cheung, S. T. M., Liang, B., Bielefeldt‐Ohmann, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj8065 · Cited by 55
Jarius, S., Bieber, N., Haas, J., & Wildemann, B. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11194-9 · Cited by 54
COVID vaccines and blood clots: five key questions
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-00998-w · Cited by 53
Göbel, C. H., Heinze, A., Karstedt, S. C., Morscheck, M., Tashiro, L., Cirkel, A., Hamid, Q. A., Halwani, R., Temsah, M.-H. A., Ziemann, M., et al. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00296-3 · Cited by 54
COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience
So, A. C. P., McGrath, H., Ting, J., Srikandarajah, K., Germanou, S., Moss, C. L., Russell, B. A., Monroy‐Iglesias, M. J., Dolly, S. O., Irshad, S., et al. (2021) · Cancers · doi:10.3390/cancers13143573 · Cited by 51
Postmortem investigation of fatalities following vaccination with COVID-19 vaccines
Schneider, J. A., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H., Kuhnen, C., Schlepper, S., Schmidt, S. C., Schulz, R., Thiele, T., et al. (2021) · International Journal of Legal Medicine · doi:10.1007/s00414-021-02706-9 · Cited by 53
Self-citationKaufman, J., Bagot, K. L., Tuckerman, J., Biezen, R., Oliver, J. R., Jos, C., Ong, D. S., Manski-Nankervis, J.-A. E., Seale, H., Sanci, L. A., et al. (2021) · Australian and New Zealand Journal of Public Health · doi:10.1111/1753-6405.13184 · Cited by 56
Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
Schönborn, L., Thiele, T., Kaderali, L., Günther, A., Hoffmann, T., Seck, S. N., Selleng, K., & Greinacher, A. (2022) · Blood · doi:10.1182/blood.2021014214 · Cited by 54
Self-citationSing, C., Tang, C. T.-L., Chui, C. S. L., Fan, M., Lai, F. T. T., Li, X., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., Hung, I. F., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26478 · Cited by 56
Approach to the Patient With Adrenal Hemorrhage
Elhassan, Y., Ronchi, C. L., Wijewickrama, P. S. A., & Baldeweg, S. E. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac672 · Cited by 53
Suresh, P., & Petchey, W. G. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243931 · Cited by 52
Cari, L., Alhosseini, M. N., Fiore, P., Pierno, S., Pacor, S., Bergamo, A., Sava, G., & Nocentini, G. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102742 · Cited by 54
Pai, M. (2022) · Seminars in Hematology · doi:10.1053/j.seminhematol.2022.02.002 · Cited by 52
Lavin, M., Elder, P. T., O’Keeffe, D., Enright, H., Ryan, E., Kelly, A. M., Elhassadi, E., McNicholl, F. P., Benson, G. M., Le, G. N., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17613 · Cited by 51
Butler, M., Tamborska, A., Wood, G. K., Ellul, M. A., Thomas, R. H., Galea, I., Pett, S. L., Singh, B., Solomon, T., Pollak, T. A., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326924 · Cited by 53
Thiele, T., Weißer, K., Schönborn, L., Funk, M. B., Weber, G., Greinacher, A., & Keller‐Stanislawski, B. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100270 · Cited by 51
Self-citationExtra-Pulmonary Complications in SARS-CoV-2 Infection: A Comprehensive Multi Organ-System Review
Louis, T. J., Qasem, A., Abdelli, L. S., & Naser, S. A. (2022) · Microorganisms · doi:10.3390/microorganisms10010153 · Cited by 52
Post COVID-19 Vaccination-Associated Neurological Complications
Assiri, S. A., Althaqafi, R. M. M., Alswat, K., Alghamdi, A., Alomairi, N. E., Nemenqani, D. M., Ibrahim, Z. S., & Elkady, A. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s343438 · Cited by 49
Stroke Associated with COVID-19 Vaccines
Kakovan, M., Shirkouhi, S. G., Zarei, M., & Andalib, S. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106440 · Cited by 54
Angeli, F., Reboldi, G., Trapasso, M., Zappa, M., Spanevello, A., & Verdecchia, P. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.06.015 · Cited by 51
New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review
Holzer, M., Krusche, M., Ruffer, N., Haberstock, H., Stephan, M., Huber, T. B., & Kötter, I. (2022) · Rheumatology International · doi:10.1007/s00296-022-05176-3 · Cited by 51
The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19
Jevtic, S. D., & Nazy, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807934 · Cited by 49
A review of adverse effects of COVID-19 vaccines
Mushtaq, H. A., Khedr, A., Koritala, T., Bartlett, B. N., Jain, N. K., & Khan, S. A. (2022) · Infezioni in Medicina · doi:10.53854/liim-3001-1 · Cited by 53
Warkentin, T. E., & Greinacher, A. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1758818 · Cited by 50
Self-citationCerebrovascular Complications of COVID-19 and COVID-19 Vaccination
Michele, M. D., Kahan, J., Berto, I., Schiavo, O. G., Iacobucci, M., Toni, D., & Merkler, A. E. (2022) · Circulation Research · doi:10.1161/circresaha.122.319954 · Cited by 54
COVID-19 Vaccines and Autoimmune Hematologic Disorders
Mingot‐Castellano, M. E., Butta, N. V., Canaro, M., Solano, M. D. C. G. D. C., Sánchez‐González, B., Jiménez‐Bárcenas, R., Pascual, C., Caballero‐Navarro, G., Ureña, L. E., González‐López, T. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10060961 · Cited by 48
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
Takuva, S. G., Takalani, A., Garrett, N., Goga, A. E., Peter, J., Louw, V. J., Opie, J., Jacobson, B. F., Sanne, I., Bekker, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107920 · Cited by 49
Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., Eden, G. L., Tee, Y. C., Benson, S. C., Masavuli, M. G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100971 · Cited by 52
D-dimer testing: A narrative review
Wauthier, L., Favresse, J., Hardy, M. J., Douxfils, J., Gal, G. L., Roy, P., van Es, N., Ay, C., Cate, H. T., Lecompte, T., et al. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.02.006 · Cited by 49
Talotta, R., & Robertson, E. S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.05.001 · Cited by 50
Aladdin, Y., Algahtani, H., & Shirah, B. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105938 · Cited by 48
Abbattista, M., Martinelli, I., & Peyvandi, F. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15493 · Cited by 48
van de Munckhof, A. A. G. A., Krzywicka, K., de Sousa, D. A., van Kammen, M. S., Heldner, M. R., Jood, K., Lindgren, E., Tatlisumak, T., Jukka Putaala, A., Hovinga, J. A. K., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15113 · Cited by 48
VITT and Second Doses of Covid-19 Vaccine
Lacy, J., Pavord, S. R., & Brown, K. E. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2118507 · Cited by 48
COVID-19 Vaccination and The Eye
Wang, M. T. M., Niederer, R. L., McGhee, C. N. J., & Danesh-Meyer, H. V. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.011 · Cited by 49
Platelet factor 4 triggers thrombo‐inflammation by bridging innate and adaptive immunity
Greinacher, A., & Warkentin, T. E. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14075 · Cited by 48
Self-citationKanack, A. J., Singh, B., George, G., Gundabolu, K., Koepsell, S. A., Abou‐Ismail, M. Y., Moser, K. A., Smock, K. J., Green, D., Major, A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26488 · Cited by 48
Myocardial infarction after COVID-19 vaccination-casual or causal?
Chatterjee, S., Ojha, U. K., Vardhan, B., & Tiwari, A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.006 · Cited by 47
Fatal cerebral haemorrhage after COVID-19 vaccine
Bjørnstad-Tuveng, T. H., Rudjord, A., & Anker, P. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0312 · Cited by 47
Iba, T., & Levy, J. H. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.08.012 · Cited by 47
The Use of COVID-19 Vaccines in Patients with SLE
Tang, W., Gartshteyn, Y., Ricker, E., Inzerillo, S., Murray, S., Khalili, L., & Askanase, A. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01046-2 · Cited by 46
Abdi, A., AlOtaiby, S., Badarin, F. A., Khraibi, A., Hamdan, H., & Nader, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112518 · Cited by 47
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Zinatizadeh, M. R., Zarandi, P. K., Zinatizadeh, M., Yousefi, M. H., Amani, J., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112527 · Cited by 51
Risk of venous thromboembolism after COVID‐19 vaccination
Houghton, D. E., Wysokiński, W. E., Casanegra, A. I., Padrnos, L. J., Shah, S., Wysokinska, E. M., Pruthi, R. K., Ashrani, A. A., Sridharan, M. R., Kreuziger, L. B., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15725 · Cited by 47
Comorbidities, Associated Diseases, and Risk Assessment in COVID‐19—A Systematic Review
Fitero, A., BUNGAU, S. G., Ţiţ, D. M., Endres, L. M., Khan, S. A., Bungău, A. F., Romanul, I. M., Vesa, C. M., Radu, A.-F., Tarce, A. G., et al. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/1571826 · Cited by 55
Zhou, L. W., Yu, A., Ngo, L. H., Hill, M. D., & Field, T. S. (2022) · Stroke · doi:10.1161/strokeaha.122.039390 · Cited by 52
Sallard, E., Zhang, W., Aydin, M., Schröer, K., & Ehrhardt, A. (2023) · Viruses · doi:10.3390/v15010204 · Cited by 47
PF4 activates the c-Mpl–Jak2 pathway in platelets
Buka, R. J., Montague, S. J., Morán, L. A., Martin, E. M., Slater, A., Watson, S. P., & Nicolson, P. L. R. (2023) · Blood · doi:10.1182/blood.2023020872 · Cited by 47
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine
Maayaan, H., Kirgner, I., Gutwein, O., Tzarfati, K. H., Rahimi‐Levene, N., Koren‐Michowitz, M., & Blickstein, D. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15420 · Cited by 46
The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia
Uzun, G., Althaus, K., Singh, A., Mӧller, P., Ziemann, U., Mengel, A., Rosenberger, P., Guthoff, M., Petzold, G. C., Müller, J., et al. (2021) · Blood · doi:10.1182/blood.2021012479 · Cited by 46
Adaptive Immunity and the Risk of Autoreactivity in COVID-19
Moody, R., Wilson, K., Flanagan, K. L., Jaworowski, A., & Plebanski, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168965 · Cited by 49
Tobaiqy, M. A., MacLure, K., Elkout, H., & Stewart, D. C. (2021) · Vaccines · doi:10.3390/vaccines9111326 · Cited by 46
Cebo, M., Dittrich, K., Fu, X., Manke, M.-C., Emschermann, F., Rheinlaender, J., von Eysmondt, H., Ferreirós, N., Sudman, J., Witte, A., et al. (2021) · Blood · doi:10.1182/blood.2021013097 · Cited by 46
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
Gabarin, N., Arnold, D. M., Nazy, I., & Warkentin, T. E. (2022) · Seminars in Hematology · doi:10.1053/j.seminhematol.2022.03.002 · Cited by 46
Self-citationJin, P., Guo, X., Chen, W., Ma, S.-H., Pan, H., Dai, L., Du, P., Wang, L., Jin, L., Chen, Y., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003953 · Cited by 46
Autoimmune Heparin-Induced Thrombocytopenia
Warkentin, T. E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216921 · Cited by 50
Self-citationAntibodies and complement are key drivers of thrombosis
Stark, K., Kilani, B., Stockhausen, S., Busse, J., Schubert, I., Tran, T.-D., Gaertner, F., Leunig, A., Pekayvaz, K., Nicolai, L., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.007 · Cited by 47
Hafeez, M. U., Ikram, M., Shafiq, Z., Sarfraz, A., Sarfraz, Z., Jaiswal, V., Sarfraz, M., & Chérrez-Ojeda, I. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211048815 · Cited by 46
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines
Hwang, J., Lee, S. B., Lee, S. W., Lee, M. H., Koyanagi, A., Jacob, L., Tizaoui, K., Yon, D. K., Shin, J. I., & Smith, L. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102681 · Cited by 45
Afshar, Z. M., Babazadeh, A., Janbakhsh, A., Afsharian, M., Saleki, K., Barary, M., & Ebrahimpour, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2273 · Cited by 45
Novak, N., Tordesillas, L., & Cabanillas, B. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1939696 · Cited by 46
Adult-onset Still's disease following COVID-19 vaccination
Leone, F., Cerasuolo, P. G., Bosello, S. L., Verardi, L., Fiori, E., Cocciolillo, F., Merlino, B., Zoli, A., & D’Agostino, M. A. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00218-6 · Cited by 45
Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients
Mani, A., & Ojha, V. (2022) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2022.05.001 · Cited by 49
VITT-like Monoclonal Gammopathy of Thrombotic Significance
Wang, J. J., Warkentin, T. E., Schönborn, L., Wheeler, M. B., Geerts, W. H., Costedoat-Chalumeau, N., Gendron, N., Ene, G. S., Lozano, M., Länger, F. P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415930 · Cited by 45
Self-citationCOVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
Yan, Z., Yang, M., & Lai, C. (2021) · Vaccines · doi:10.3390/vaccines9101097 · Cited by 48
Hess, S., Lancsar, E., Mariel, P., Meyerhoff, J., Song, F., van den Broek‐Altenburg, E. M., Alaba, O. A., Amaris, G., Arellana, J., Basso, L. J., et al. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.114800 · Cited by 47
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W., & Greeve, I. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10599-2 · Cited by 44
Self-citationKantarcıoğlu, B., Iqbal, O., Walenga, J. M., Lewis, B., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Tafur, A. J., Ramacciotti, E., et al. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211021498 · Cited by 45
Tiede, A., Althaus, K., Sachs, U. J., Cooper, N., Czwalinna, A., Müller, J., & Pötzsch, B. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1535-9002 · Cited by 44
Metadata
- Authors
- Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Greinacher, Andreas
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-03
- Volume
- 384
- Issue
- 22
- Pages
- 2092-2101
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8095372
- OpenAlex
- W3140226555
- Cited by
- 2,259
- References
- 27
- Citations by year
- 2026: 77 · 2025: 139 · 2024: 171 · 2023: 297 · 2022: 725 · 2021: 848
- FWCI
- 479.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (Projektnummer 374031971 – TRR 240)
- Topics
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- ChAdOx1 nCoV-19 vaccine, AstraZeneca COVID-19 vaccine, vaccine-associated thrombosis, platelet factor 4, PF4/heparin antibodies, platelet-activating antibodies, cerebral venous thrombosis, pulmonary embolism, splanchnic vein thrombosis, disseminated intravascular coagulation, heparin, Fc receptor blockade, gamma globulin
- MeSH terms
- COVID-19 Vaccines, ChAdOx1 nCoV-19, Adult, Autoantibodies, Autoimmune Diseases, Blood Chemical Analysis, Disseminated Intravascular Coagulation, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Platelet Factor 4, Thrombocytopenia, Thrombosis, Platelet Activation, Fatal Outcome, Intracranial Hemorrhages, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
